Top Abstract Purchase Related
Home
>
Node
>
Subnode

Optimal drugs for HIPEC in different tumors

De Bree, E.

Journal of Buon Official Journal of the Balkan Union of Oncology 20(Suppl 1): S40-S46

2015

ISSN/ISBN: 1107-0625
PMID: 26051331
Document Number: 682058
Although there is adequate evidence to support treatment of primary and secondary peritoneal surface malignancies with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), the latter procedure is still far from standardized and optimization of its aspects may be warranted. Significant variations remain in HIPEC procedures and include also the drug choice. In this manuscript the characteristics of the optimal HIPEC drug will be discussed. Subsequently, the drug choice for HIPEC treatment of different peritoneal surface malignancies will be briefly analyzed. Prospective randomized trials are warranted to determine which drug is the most effective for HIPEC in each type of peritoneal surface malignancy. In the future, it would be of major significance when the choice of the most optimal drug in HIPEC may be tailored to the patient's individual tumor by adequate drug sensitivity testing of the tumor cells.

Document emailed within 1 workday
Secure & encrypted payments

Sperti, C.; Merigliano, S.; Moletta, L. 2015: Metastatic pancreatic tumors: what is the optimal treatment? Minerva Chirurgica 70(2): 131-139
Bozhenkov, I.G. 1986: Optimal tactics in the cryosurgical treatment of skin tumors with suspicion of melanoma Klinicheskaia Khirurgiia 5: 42-43
Yoshida, N.; Nakamura, M.; Fukui, M.; Morisada, S.; Ogino, S.; Inaba, M.; Tsukagoshi, S.; Sakurai, Y. 1983: Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors Cancer Research 43(12 Part 1): 5851-5856
Liu, D.; Li, J.; Liu, X. 1995: Steady-state characteristics and optimal dosage regimens for Michaelis-Menten elimination drugs Hua Xi Yi Ke Da Xue Xue Bao 26(1): 61-65
Zatelli, R.; Camerini, G.; Tonini, P.; Voghenzi, A. 1989: Computerized determination of pharmacokinetic constants in a biocompartmental model aimed at the optimal clinical use of drugs Bollettino della Societa Italiana di Biologia Sperimentale 65(6): 529-534
Chino, H.; Hagiwara, E.; Sekine, A.; Kitamura, H.; Baba, T.; Shinohara, T.; Komatsu, S.; Ogura, T. 2016: [compliance Rate of Standard Treatment Regimen and Optimal Dose of Anti-Tuberculosis Drugs in Late Elderly Patients with Pulmonary Tuberculosis Kekkaku: 91(5): 495-502
Kitano, I. 1980: A newly developed Sapporo IABP control system and experimental studies on optimal condition-especially "optimal deflation time" Nihon Kyobu Geka Gakkai 28(1): 111-123
Zeamari, S.; Floot, B.; van der Vange, N.; Stewart, F.A. 2003: Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) Anticancer Research 23(2b): 1643-1648
Antos, F.; Dytrych, P.; Vítek, P.; Ryska, O.; Marvan, J.; Serclovlá, Z. 2010: Malignant ascites--optional management using hyperthermic peroperative chemotherapy (HIPEC) Rozhledy V Chirurgii: Mesicnik Ceskoslovenske Chirurgicke Spolecnosti 89(4): 237-241
Khubua, I.; Aladashvili, A.; Pantsulaia, I. 2018: Hipec in the Management of Peritoneal Carcinomatosis and Potential Markers of Treatment Efficiency Georgian Medical News 284: 37-41
Mounir, D.; Ali, C.; Abdelmajid, D. 2000: Ambulatory anesthesia: which optimal organization for optimal safety? La Tunisie Medicale 78(4): 235-240
Robella, M.; Vaira, M.; Mellano, A.; Marsanic, P.; Cinquegrana, A.; Borsano, A.; Barbera, M.; Caneparo, A.; Siatis, D.; Sottile, A.; De Simone, M. 2014: Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC Minerva Chirurgica 69(1): 9-15
Di Miceli, D.; Alfieri, S.; Caprino, P.; Menghi, R.; Quero, G.; Cina, C.; Pericoli Ridolfini, M.; Doglietto, G.B. 2012: Complications related to hyperthermia during hypertermic intraoperative intraperitoneal chemiotherapy (HIPEC) treatment. do they exist? European Review for Medical and Pharmacological Sciences 16(6): 737-742
Budak, A.Majsec.; Škegro, M.; Majerović, M.; Smud, D.; Jelinčić, Željko.; Kinda, E.; Kekez, T.; Augustin, G.; Silovski, H.; Matošević, P.; Bruketa, T. 2015: First synchronous liver resection as a part of cytoreductive surgery, peritonectomy and HIPEC in Croatia--case report Lijecnicki Vjesnik 137(3-4): 87-90
Ben-Yaacov, A.; Nevo, Y.; Nissan, A. 2019: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (Hipec) for Peritoneal Metastasis of Gastro-Intestinal Origin Harefuah 158(4): 263-267
Pallas, N.; Karamveri, C.; Kyziridis, D.; Hristakis, C.; Kyriakopoulos, V.; Kalakonas, A.; Vaikos, D.; Tentes, A.-A.K. 2017: Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis Journal of Buon: Official Journal of the Balkan Union of Oncology 22(6): 1547-1553
Robella, M.; Vaira, M.; Marsanic, P.; Mellano, A.; Borsano, A.; Cinquegrana, A.; Sottile, A.; De Simone, M. 2014: Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) Minerva Chirurgica 69(1): 27-35
Furue, H. 1977: Drugs used in the treatment of malignant tumors Nursing Technique 23(6): 112-129
Garrett, C. 2013: New drugs for gastrointestinal stromal tumors Clinical Advances in Hematology and Oncology: H&o 11(10): 656-658
Höffken, K.; Schmidt, C.G. 1986: Cytostatic drugs in the therapy of gastrointestinal tumors Medizinische Klinik 81(4): 135-141